Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

VM 26 and VP 16-213: a comparative analysis.

M Rozencweig, D D Von Hoff, J E Henney

|July 1, 1977

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Same author

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Cancer chemotherapy and pharmacology·2014

Same author

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012

VM 26 and VP 16-213, epipodophyllotoxin analogs, show no significant differences in experimental or clinical features. Further research on analogous cytotoxic agents is recommended to guide future drug development.

Area of Science:

Pharmacology
Oncology
Medicinal Chemistry

Background:

Epipodophyllotoxin analogs like VM 26 and VP 16-213 are utilized in cancer therapy.
Understanding the comparative profiles of these agents is crucial for optimizing treatment strategies.

Purpose of the Study:

To conduct a comparative analysis of the experimental and clinical characteristics of VM 26 and VP 16-213.
To identify any significant differences that may inform their distinct therapeutic applications.

Main Methods:

Comparative analysis of existing experimental data.
Review of clinical trial outcomes and patient data for both VM 26 and VP 16-213.

Main Results:

No significant differences were identified between VM 26 and VP 16-213 in their experimental or clinical profiles.

Related Experiment Videos

The study highlights the similarity in efficacy and toxicity between these two epipodophyllotoxin analogs.

Conclusions:

The current data does not support a distinct rationale for the separate development of VM 26 and VP 16-213.
Further investigation into other classes of cytotoxic agents may provide insights into developing analogous compounds with differentiated therapeutic advantages.